enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Dabrafenib - Wikipedia

    en.wikipedia.org/wiki/Dabrafenib

    Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.

  3. List of countries by quality of healthcare - Wikipedia

    en.wikipedia.org/wiki/List_of_countries_by...

    The 5-year observed survival rate refers to the percentage of patients who live at least five years after being diagnosed with cancer. Many of these patients live ...

  4. Trametinib - Wikipedia

    en.wikipedia.org/wiki/Trametinib

    Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]

  5. List of countries by cancer rate - Wikipedia

    en.wikipedia.org/wiki/List_of_countries_by...

    This is a list of countries by cancer rate, as measured variously by the number of new cancer cases (frequency), ... Canada: 292,098 345.9 232,074 292.4

  6. Cancer survival rates - Wikipedia

    en.wikipedia.org/wiki/Cancer_survival_rates

    Survival rates for most childhood cancers have improved, with a notable improvement in acute lymphoblastic leukemia (the most common childhood cancer). Due to improved treatment, the 5-year survival rate for acute lymphoblastic leukemia has increased from less than 10% in the 1960s to about 90% during the time period 2003-2009.

  7. Tissue-agnostic cancer drug - Wikipedia

    en.wikipedia.org/wiki/Tissue-agnostic_cancer_drug

    Dabrafenib and trametinib have been approved as tissue-agnostic drugs for solid tumors that are B-RAF positive. [ 16 ] Tissue-agnostic cancer drugs that are under development as of May 2022 [update] include Selitrectinib (Loxo-195) and anti- ERBB3 antibodies.

  8. Survival rate - Wikipedia

    en.wikipedia.org/wiki/Survival_rate

    Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.

  9. Progression-free survival - Wikipedia

    en.wikipedia.org/wiki/Progression-free_survival

    Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.